Physician profile
Anthony Marquinez
NPI 1699742551
$2,652.68
in general payments reported to CMS, 2019-2025
31 companies · $642 in 2025
The $642 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $353 · 2023: $780 · 2024: $698 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.84 |
| Education | $145.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $604.08 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $202.56 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $202.42 | 2021-2025 | |
| Abbvie INC. | $164.53 | 2022-2025 | |
| Tg Therapeutics, INC. | $151.44 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $147.88 | 2021-2025 | Ultomiris |
| Argenx US, INC. | $122.82 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $121.91 | 2022-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $121.12 | 2023-2025 | |
| Biogen, INC. | $118.53 | 2021-2024 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $110.31 | 2022-2025 | |
| Celgene Corporation | $81.46 | 2021-2025 | Zeposia |
| Csl Behring | $59.86 | 2021-2023 | Hizentra |
| Amgen INC. | $48.69 | 2022-2023 | Aimovig |
| Emd Serono, INC. | $46.82 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $34.53 | 2025 | |
| Genentech USA, INC. | $31.74 | 2023-2024 | Ocrevus, Enspryng |
| Astrazeneca Pharmaceuticals LP | $30.07 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $29.33 | 2023-2025 | Keveyis |
| Janssen Pharmaceuticals, INC | $28.70 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $27.45 | 2024 | |
| Grifols USA, LLC | $19.16 | 2023 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $19.11 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $18.30 | 2025 | Symbravo |
| Acadia Pharmaceuticals INC | $18.19 | 2025 | Nuplazid |
| Neurelis, INC. | $17.07 | 2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $16.62 | 2023 | Nuedexta |
| Lilly USA, LLC | $16.03 | 2023 | Reyvow, Emgality |
| Biohaven Pharmaceuticals, INC. | $15.56 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.46 | 2022 | |
| Impel Pharmaceuticals LLC | $11.93 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Marquinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.